Aelix Therapeutics
Barcelona
About Aelix Therapeutics
Aelix Therapeutics develops therapeutic vaccines and immunotherapies to treat HIV infection. The company is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was created under the leadership of its founders, Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Mr. Jordi Naval; all of whom have several decades of experience in HIV and biotech development. The company’s know-how will further expand through unique immunogen designs. It will also benefit from ready access to large cohorts of HIV infected patients in several continents through its partnership with the HIVACAT consortium.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $14.7M
- Last round: Series Unknown (Sep 2021)
- Website: aelixtherapeutics.com
- Phone: (514) 367 1212
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/aelix-therapeutics-221571 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.